Navigation Links
Stemedica Completes Meeting with the FDA
Date:10/15/2009

Stemedica Cell Technologies, Inc. announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke. Based on a meeting October 13, 2009 with the FDA, Stemedica is planning to file an IND application in the first quarter of 2010.

San Diego, CA (PRWEB) October 15, 2009 -- Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke. Based on a meeting October 13, 2009 with the FDA, Stemedica is planning to file an IND application in the first quarter of 2010.

The proposed clinical trial will be a Phase I/II dose escalation and safety clinical trial using allogeneic mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke. The patient population will include individuals with a clinical diagnosis of chronic neurological or age-related neurodegenerative disease with significant functional or neurologic impairment that confines the subject to a wheelchair or requires the subject to have home nursing care or assistance with the general activities of daily living. The proposed trial will take place at medical centers within the United States.

"This is an important milestone for Stemedica," said
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
2. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
3. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
4. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
5. Stemedica Requests Pre-IND Meeting With FDA
6. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
7. Renowned Stem Cell Researcher Files Study Results With Stemedica
8. CIRM Completes Briefing Visit to Stemedica Cell Technologies
9. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
10. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
11. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Completes Meeting with the FDA
(Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
(Date:7/24/2014)... A research team led by group leader Yung-Eun ... technology to synthesize sulfur-doped and nitrogen-doped graphenes which ... secondary batteries and fuel cells. Yung-Eun Sung is ... Nanoparticle Research at Institute for Basic Science* (IBS) ... , This achievement has great significance with regards ...
Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... Researcher Appreciation Event ... ... PHOENIX, Oct. 3 ThirdBiotech Inc., http://www.thirdbiotech.com, a biotechnology incubator ... Appreciation Event to be held on Thursday, October 23rd, 2008,between noon and ...
... http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), a leading ... the US, today announced that the,Company will present at ... on Tuesday, October 7, 2008 at 10:30 a.m. ET. ... York Hotel in the Morosco Room., The Maxim ...
... Support R&D Efforts and Clinical Trials Advancing,the ... Oct. 3 Micromet, Inc. (Nasdaq:,MITI) ("Micromet" ... proprietary antibodies for the treatment of cancer, ... has closed its previously,announced $40 million private ...
Cached Biology Technology:First Annual Arizona Biotech Day Announced for October 23rd 2008 2First Annual Arizona Biotech Day Announced for October 23rd 2008 3AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 2AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 3Micromet Closes $40 Million Private Equity Placement 2Micromet Closes $40 Million Private Equity Placement 3Micromet Closes $40 Million Private Equity Placement 4
(Date:7/25/2014)... is a complex congenital central nervous system disease ... the neural tubes during the embryonic phase. Many ... fecal incontinence and neurocognitive retardation. Such problems decrease ... life. Researchers at Ankara Physical Medicine and Rehabilitation ... performance in children with SB, using the Pediatric ...
(Date:7/25/2014)... girls reach puberty is influenced by ,imprinted genes,a subset of ... gene. This is the first evidence that imprinted genes ... of this study were published today in the journal ... menarche, is a marker for the timing of puberty in ... varies between girls, is an inherited trait, and is linked ...
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... European College of Neuropsychopharmacology (ECNP) is pleased to ... 2009 ECNP Neuropsychopharmacology Award in Basic Science Research ... into the neurochemical basis of substance addiction. ... in the field of neuropsychopharmacology and its closely ...
... Researchers have made significant advances in the treatment of metastatic ... treat successfully once it has started to spread according ... congress, ECCO 15 ESMO 34 [1], in Berlin on ... seen rapid and dramatic shrinking of metastatic tumours in patients ...
... research team at the National Institute of Standards and ... possible cancer therapy has uncovered a delicate balancing act ... says they should be. Just like individuals in a ... because they get close together, but not too close. ...
Cached Biology News:Trial of new treatment for advanced melanoma shows rapid shrinking of tumors 2Trial of new treatment for advanced melanoma shows rapid shrinking of tumors 3Therapeutic nanoparticles give new meaning to sugar-coating medicine 2
... 75 x ... recommended for immunohistochemistry of paraffin-embedded sections, ... at one end, markings ... normal procedures, precleaned, ...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Donor feline serum and plasma...
Request Info...
Biology Products: